Pentosan Polysulfate common uses, half-life, side effects and more

Pentosan polysulfate sodium is a sulfated sugar polymer made from beech wood xylan. It is not a peptide. It is not even one molecule but a mixture of chains of different lengths. The oral capsule is FDA-approved by prescription for the bladder pain of interstitial cystitis. It is the only oral drug approved for that condition in the United States. People inject it for joint pain, drawing on osteoarthritis research and on animal practice. No regulator anywhere has approved an injectable pentosan product for people. The injectable sold for human joint use is veterinary product, correctly labeled for horses or dogs. Long-term use is tied to a form of retinal damage that can keep getting worse after the drug is stopped.

• Bladder pain of interstitial cystitis
• Joint pain and osteoarthritis
• Stiffness and mobility
• Tendon and other musculoskeletal pain by extension

Three times a day by mouth and once or twice a week by injection for four to six weeks

The approved oral dose is 100 mg three times a day on an empty stomach. Human osteoarthritis studies injected 2 to 3 mg per kilogram under the skin or into muscle once or twice a week. That is roughly 140 to 210 mg for a 70 kg adult. The approved horse product is 3 mg per kilogram into muscle once a week for four weeks. A dose-finding study in dogs found 5 mg per kilogram worked worse than 3 mg. More is not better. The oral and injected numbers are not the same currency. An oral dose reaches the blood as intact drug at under 1 percent. A weekly injection therefore delivers far more active drug than the daily capsules despite the smaller number on the label.

• An oral dose reaches the blood mostly as inactive fragments rather than intact drug
• The injected exposure is an estimate because nobody has measured how much of an injected dose reaches the blood in people or in any animal
• The oral drug's long safety record was built on a route that delivers very little active drug and does not carry over to injection
• Joint protocols inject under the skin or into muscle rather than into the joint

No usable plasma half-life exists for this drug. The 20 to 34 hour figure quoted for the oral route measures total radioactivity. No test for the intact drug exists. That radioactivity is mostly breakdown products. The drug clears from the blood quickly after an injection into a vein. It is also a mixture of different chain lengths that clear at different rates. A single number would be wrong for most of it.

Oral capsules are kept at 20 to 25 degrees Celsius with short excursions allowed from 15 to 30.

• Long-term use can cause retinal damage that shows up first as trouble reading and slow adjustment to dim light while sharp vision still tests normal
• Bruising, nosebleeds, gum bleeding, and rectal bleeding can occur because the drug thins the blood
• Diarrhea, nausea, abdominal pain, indigestion, headache, and dizziness are the common oral complaints
• Hair loss appears in about 4 percent, usually a single bald patch rather than thinning, within the first few weeks
• Injection carries an added risk of a delayed immune reaction that drops platelets and can cause clots or bleeding
• Liver enzyme rises, low platelets, and low blood counts have been reported

Pentosan polysulfate is a heparin-like sulfated sugar with about one fifteenth the blood-thinning strength of heparin. That figure is an average across a mixture whose chains behave differently by length. The label states plainly that how it helps the bladder is not known. The idea is that it coats the bladder lining and stands in for a protective sugar layer that lets irritants through. The evidence that it reaches or repairs that lining comes from animals rather than people. The proposed actions in joints are lower inflammation and slower cartilage breakdown, shown in the laboratory rather than demonstrated in people. Why it damages the retina is an open question. Recent laboratory work points at direct harm to the pigment cells at the back of the eye.

The approval rests on old and modest trials. The strongest modern evidence runs against it. The FDA required a confirmatory trial after approval. That trial stopped early in 2015 after an interim look found it was unlikely to succeed. A meaningful symptom improvement reached 40.7 percent on placebo against 39.8 and 42.6 percent on the two drug doses. The current label still does not mention it. An independent 2020 review found no evidence the drug improved symptoms or reduced pain, frequency, or nighttime urination. It rated that evidence low to very low. That means uncertain rather than disproven. The one favorable pooled analysis was written for the European approval by authors including staff of the company that sells the drug there. The osteoarthritis case is weaker still. No completed human trial with a pain or function result has topped 114 patients. Both controlled dog trials found no benefit. A 600-person injection trial has finished without reporting. That literature comes almost entirely from a few linked Australian groups and one company.

• Long-term use calls for eye imaging at the start and periodically because it can cause retinal damage that may be permanent and can keep worsening after the drug is stopped
• Injected cases of retinal damage appeared at a small fraction of the cumulative lifetime dose that harms oral users
• The drug thins the blood and should be reviewed before surgery, dental work, or use with blood thinners, aspirin, or anti-inflammatories
• Bleeding risk is real even at a standard dose because injection at the approved horse dose prolonged clotting in every animal tested
• Active bleeding, low platelets, a bleeding disorder, ulcers, an aneurysm, liver disease, kidney disease, or prior heparin-induced low platelets all need a clinician's review first
• Pregnancy and breastfeeding have no human safety data and animal studies used the oral drug